Cargando…

Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study

BACKGROUND: Patient groups represent the interest of their members when it comes to drug funding. Many patient groups receive grants from pharmaceutical companies that make products being considered for funding. This research examines whether there is an association between the positions that Canadi...

Descripción completa

Detalles Bibliográficos
Autor principal: Lexchin, Joel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377138/
https://www.ncbi.nlm.nih.gov/pubmed/30768629
http://dx.doi.org/10.1371/journal.pone.0212399
_version_ 1783395702372564992
author Lexchin, Joel
author_facet Lexchin, Joel
author_sort Lexchin, Joel
collection PubMed
description BACKGROUND: Patient groups represent the interest of their members when it comes to drug funding. Many patient groups receive grants from pharmaceutical companies that make products being considered for funding. This research examines whether there is an association between the positions that Canadian groups take about the products and conflicts of interest with the companies. METHODS: The Common Drug Review (CDR) and panCanadian Oncology Drug Review (pCODR) make recommendations to Canadian provincial and federal drug plans about funding particular drug-indications. Both utilize input from patient groups in making their recommendations. Patient group submissions are available from both organizations and these submissions contain statements about conflicts of interest. Views of the patient groups, with and without a conflict with the company making the drug under consideration and without any conflicts at all, were assessed and then compared with the recommendations from CDR and pCODR. RESULTS: There was a total of 222 reports for drug-indications. There were 372 submissions from 93 different patient groups. Groups declared a total of 1896 conflicts with drug companies in 324 (87.1%) individual submissions. There were 268 submissions where groups declared a conflict with the company making the product or said they had no conflict. Irrespective of whether there was a conflict, the views of patient groups about the drug-indications under consideration were the same. There was no statistically significant difference between views of patient groups and the recommendations from CDR and/or pCODR. CONCLUSIONS: The large majority of patient groups making submissions about funding of particular drug-indications had conflicts with the companies making the products and their views about the products were almost always positive. This association between funding and views needs to be further investigated to determine if a true cause and effect exists.
format Online
Article
Text
id pubmed-6377138
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-63771382019-03-01 Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study Lexchin, Joel PLoS One Research Article BACKGROUND: Patient groups represent the interest of their members when it comes to drug funding. Many patient groups receive grants from pharmaceutical companies that make products being considered for funding. This research examines whether there is an association between the positions that Canadian groups take about the products and conflicts of interest with the companies. METHODS: The Common Drug Review (CDR) and panCanadian Oncology Drug Review (pCODR) make recommendations to Canadian provincial and federal drug plans about funding particular drug-indications. Both utilize input from patient groups in making their recommendations. Patient group submissions are available from both organizations and these submissions contain statements about conflicts of interest. Views of the patient groups, with and without a conflict with the company making the drug under consideration and without any conflicts at all, were assessed and then compared with the recommendations from CDR and pCODR. RESULTS: There was a total of 222 reports for drug-indications. There were 372 submissions from 93 different patient groups. Groups declared a total of 1896 conflicts with drug companies in 324 (87.1%) individual submissions. There were 268 submissions where groups declared a conflict with the company making the product or said they had no conflict. Irrespective of whether there was a conflict, the views of patient groups about the drug-indications under consideration were the same. There was no statistically significant difference between views of patient groups and the recommendations from CDR and/or pCODR. CONCLUSIONS: The large majority of patient groups making submissions about funding of particular drug-indications had conflicts with the companies making the products and their views about the products were almost always positive. This association between funding and views needs to be further investigated to determine if a true cause and effect exists. Public Library of Science 2019-02-15 /pmc/articles/PMC6377138/ /pubmed/30768629 http://dx.doi.org/10.1371/journal.pone.0212399 Text en © 2019 Joel Lexchin http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Lexchin, Joel
Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study
title Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study
title_full Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study
title_fullStr Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study
title_full_unstemmed Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study
title_short Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study
title_sort association between commercial funding of canadian patient groups and their views about funding of medicines: an observational study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377138/
https://www.ncbi.nlm.nih.gov/pubmed/30768629
http://dx.doi.org/10.1371/journal.pone.0212399
work_keys_str_mv AT lexchinjoel associationbetweencommercialfundingofcanadianpatientgroupsandtheirviewsaboutfundingofmedicinesanobservationalstudy